



## Patrys Hosts 2<sup>nd</sup> IgM Conference

- Patrys is a leader in IgM antibody development
- Patrys' antibodies were a highlight of the 2<sup>nd</sup> IgM conference

**Melbourne, Australia; 6 May, 2013:** Patrys Limited (ASX: PAB), a clinical stage biopharmaceutical company, hosted the 2nd IgM Conference "*The New Paradigm: IgM from Bench to Clinic*" in Frankfurt, Germany from 23<sup>rd</sup>-24<sup>th</sup> April 2013.

The event brought together the increasingly active and growing IgM antibody community to discuss recent advances and challenges facing the discovery and development of IgM antibody therapies and technologies. Researchers, bio-manufacturing experts and clinicians delivered 23 presentations on the basic science and isolation of IgM antibodies, their development, formulation and clinical development. Patrys is excited to be the leading player in the IgM space with Patrys' antibodies featuring in a number of presentations.

Dr. Peter Jones from the John Wayne Cancer Institute commented: "Patrys organised an outstanding conference updating all attendees on the treatment of disease with human IgM antibodies. We are now at a pivotal point with IgMs in clinical trials for several diseases including Patrys' PAT-SM6 which is in a Phase I/IIa trial for multiple myeloma. IgMs will soon secure their place as cancer treatments. The conference clearly established that this long ignored antibody class has great potential."

Dr Frank Hensel, Patrys' VP of Research and Development, further commented, "Patrys is proud to once again host this important event. Participants discussed topics aimed at investigating the full potential of IgM antibodies. New frontiers have been explored and some fundamental questions in antibody targeting, production and mechanisms of action and resistance tackled. I am confident that the meeting will be even bigger in the future, and will develop into the core event for the IgM community. "

The meeting was sponsored by Patrys, BIA Separations, Laureate Biopharma, Bio-Rad Laboratories, CMC Biologics, Sartorius, JSR Life Sciences, PALL Life Sciences and mAbs.

More information about the conference can be found at <http://events.dechema.de/events/en/antibody.html>.

**-Ends-**

**For further information, please contact:**

Patrys Limited:

Dr. Marie Roskrow  
Chief Executive Officer  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

Patrys Limited:

Ms. Valentina Dubljevic  
Senior Director of Operations  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).